ArticleBMC cancer2025
Global, regional, and national burden of kidney cancer and attributable risk factors in adults aged 65 years and older from 1990 to 2021 and projections to 2040.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Integrative analysis prioritizes proteins associated with renal cell carcinoma and its risk factors.JNCI cancer spectrum · 2026Article
- Exploring the mechanism by which triphenyl phosphate promotes malignant phenotypes in bladder and kidney cancer through MMP9 based on bioinformatics analysis and experimental validation.Clinical and experimental medicine · 2026Article
- Joint effects and dynamic trajectories of metabolic insulin resistance and systemic inflammation in the risk of renal cell carcinoma: a UK Biobank cohort analysis.World journal of urology · 2026Article
- Targeting urological cancers with CAR-T cell therapy: current landscape and future directions.Journal of translational medicine · 2026Review
- Case Report: A rare case of intestinal and mucinous-type renal pelvis adenocarcinoma masked by complex renal calculi: a diagnostic dilemma and therapeutic challenge.Frontiers in oncology · 2026Article
- Global burden and temporal trends of kidney cancer among children from 1990 to 2021: an analysis with projections to 2036.Frontiers in pediatrics · 2026Article
- Global, regional, and national burden of kidney cancer, 1990 to 2021, and projections to 2050: A Global Burden of Disease Study 2021.Medicine · 2025Article
- Global, regional, national burden, trends and health inequality of neglected tropical diseases and malaria from 1990 to 2021.BMC infectious diseases · 2025Article
- Global and regional burden of kidney cancer from 1990 to 2021: analysis and future predictions based on global burden of disease study.BMC cancer · 2025Article
- Burden of kidney cancer in China from 1990 to 2021 and predictions for 2036: an age-period-cohort analysis of global burden of disease study 2021.BMC public health · 2025Article
- Molecular Genetics of Renal Cell Carcinoma: A Narrative Review Focused on Clinical Relevance.Current oncology (Toronto, Ont.) · 2025Review
- Temporal trends in the incidence and mortality of kidney cancer across BRICS from 1990 to 2021: an age-period-cohort analysis.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIdentifying the past and future burden of kidney cancer (KC) and its temporal trends among older adults (≥ 65 years) at global, regional, and national levels is critical for effective prevention strategies.
methodsThe age-standardized incidence, prevalence, mortality, and disability-adjusted life years (DALYs) were calculated using data from the Global Burden of Disease (GBD) study from 1990 to 2021. These indicators were stratified by sex, age, and socio-demographic index (SDI). The correlation between these indicators and SDI was assessed. Temporal trends were quantified using the annual average percentage change (AAPC), and future trends from 2022 to 2040 were predicted using the Bayesian age-period-cohort (BAPC) model.
resultsThe global age-standardized incidence rate (ASIR) of KC among older adults increased from 21.73 per 100,000 people in 1990 to 26.74 per 100,000 people in 2021, with an AAPC of 0.67%. Age-standardized DALYs rate (ASDR) remained stable, while significant increases were observed in age-standardized prevalence (AAPC = 1.24%, 95%CI: 1.14-1.34%) and mortality rate (AAPC = 0.13%, 95%CI: 0.05-0.22%). From 1990 to 2021, males consistently exhibited a higher disease burden than females, additionally, the ASIR of KC increased significantly in all age subgroups. Regions with higher SDI levels also showed a greater disease burden, while Oceania had the lowest burden of KC in 2021. The ASIR increased in almost all countries and territories. Czechia showed the highest ASIR (92.25 per 100,000 people) and ASDR (819.88 per 100,000 people). Smoking and high body mass index (BMI) remained significant risk factors for DALYs and mortality in the older population, and their effects were greatest in high SDI region. Furthermore, the burden of KC is expected to continue to decline through 2040.
conclusionsThe global burden of KC among older adults increased from 1990 to 2021, with notable regional and national variations. However, it is projected to continue to decline through 2040. The management of smoking and high BMI remain major challenges for people with KC, necessitating targeted clinical guidelines, particularly focusing on males and the older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.